New asthma inhaler could offer better control for kids

NCT ID NCT05562466

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 32 times

Summary

This study compares a new combination inhaler (QMF149) to a standard asthma inhaler (budesonide) in 200 children aged 6 to 12 with asthma. Each child will try both treatments for 12 weeks to see which one improves lung function and symptom control more. The goal is to find a more effective daily treatment to manage asthma in children.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

CABA, Buenos Aires, C1122AAK, Argentina
Novartis Investigative Site
RECRUITING

CABA, Buenos Aires, C1414AIF, Argentina
Novartis Investigative Site
RECRUITING

CABA, Buenos Aires, C1425BEN, Argentina
Novartis Investigative Site
RECRUITING

Rosario, Santa Fe Province, 2000, Argentina
Novartis Investigative Site
RECRUITING

Rosario, Santa Fe Province, S2000JKR, Argentina
Novartis Investigative Site
RECRUITING

Mendoza, 5500, Argentina
Novartis Investigative Site
RECRUITING

Graz, 8036, Austria
Novartis Investigative Site
RECRUITING

Salzburg, 5020, Austria
Novartis Investigative Site
RECRUITING

Sankt Pölten, 3100, Austria
Novartis Investigative Site
RECRUITING

Rousse, 7002, Bulgaria
Novartis Investigative Site
RECRUITING

Sevlievo, 5400, Bulgaria
Novartis Investigative Site
RECRUITING

Bucaramanga, Santander Department, 680001, Colombia
Novartis Investigative Site
RECRUITING

Ibague, Tolima Department, 730006, Colombia
Novartis Investigative Site
RECRUITING

Cali, Valle del Cauca Department, 760001, Colombia
Novartis Investigative Site
RECRUITING

Plzen Bory, 301 00, Czechia
Novartis Investigative Site
RECRUITING

Prague, 128 08, Czechia
Novartis Investigative Site
RECRUITING

Athens, 115 27, Greece
Novartis Investigative Site
RECRUITING

Chaïdári, 124 62, Greece
Novartis Investigative Site
RECRUITING

Heraklion Crete., 715 00, Greece
Novartis Investigative Site
RECRUITING

Pátrai, 265 04, Greece
Novartis Investigative Site
RECRUITING

Thessaloniki, 546 42, Greece
Novartis Investigative Site
RECRUITING

Guatemala City, GTM, 01011, Guatemala
Novartis Investigative Site
RECRUITING

Guatemala City, 01010, Guatemala
Novartis Investigative Site
RECRUITING

Budapest, 1033, Hungary
Novartis Investigative Site
RECRUITING

Gödöllő, 2100, Hungary
Novartis Investigative Site
RECRUITING

Szeged, 6720, Hungary
Novartis Investigative Site
RECRUITING

Szigetvár, 7900, Hungary
Novartis Investigative Site
RECRUITING

Brescia, BS, 25123, Italy
Novartis Investigative Site
RECRUITING

Catania, CT, 95123, Italy
Novartis Investigative Site
RECRUITING

Florence, FI, 50139, Italy
Novartis Investigative Site
WITHDRAWN

Pavia, PV, 27100, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00161, Italy
Novartis Investigative Site
RECRUITING

Naples, 80138, Italy
Novartis Investigative Site
RECRUITING

Guadalajara, Jalisco, 44100, Mexico
Novartis Investigative Site
RECRUITING

Guadalajara, Jalisco, 44130, Mexico
Novartis Investigative Site
RECRUITING

San Juan del Río, Querétaro, 76800, Mexico
Novartis Investigative Site
RECRUITING

Villahermosa, Tabasco, 86035, Mexico
Novartis Investigative Site
RECRUITING

Querétaro, 76000, Mexico
Novartis Investigative Site
RECRUITING

Panama City, 8185, Panama
Novartis Investigative Site
RECRUITING

Lisbon, 1649-035, Portugal
Novartis Investigative Site
RECRUITING

Lisbon, 1998-018, Portugal
Novartis Investigative Site
WITHDRAWN

Porto, 4099-001, Portugal
Novartis Investigative Site
RECRUITING

Porto, 4100-180, Portugal
Novartis Investigative Site
WITHDRAWN

Timișoara, Timiș County, 300723, Romania
Novartis Investigative Site
RECRUITING

Bucharest, 050152, Romania
Novartis Investigative Site
RECRUITING

Bloemfontein, Free State, 9301, South Africa
Novartis Investigative Site
RECRUITING

Centurion, Gauteng, 0157, South Africa
Novartis Investigative Site
RECRUITING

Pretoria, Gauteng, 0181, South Africa
Novartis Investigative Site
RECRUITING

Raslouw Centurion, Gauteng, 0157, South Africa
Novartis Investigative Site
RECRUITING

Cape Town, Western Cape, 7130, South Africa
Novartis Investigative Site
RECRUITING

George, Western Cape, 6529, South Africa
Novartis Investigative Site
RECRUITING

Cape Town, Western Province, 7700, South Africa
Novartis Investigative Site
RECRUITING

Cape Town, 7531, South Africa
Novartis Investigative Site
RECRUITING

Esplugues, Barcelona, 08950, Spain
Novartis Investigative Site
RECRUITING

Sabadell, Barcelona, 08208, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Córdoba, 14004, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28034, Spain
Novartis Investigative Site
RECRUITING

Málaga, 29011, Spain
Novartis Investigative Site
RECRUITING

Haiphong, 180000, Vietnam
Novartis Investigative Site
RECRUITING

Hanoi, 100000, Vietnam
Novartis Investigative Site
RECRUITING

Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

ASTHMA